| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Soumia Majait, Emma C E Meessen, Mark Davids, Youssef Chahid, Steven W Olde Damink, Frank G Schaap, Ellis Marleen Kemper, Max Nieuwdorp, Maarten R Soeter. Age-Dependent Differences in Postprandial Bile-Acid Metabolism and the Role of the Gut Microbiome. Microorganisms. vol 12. issue 4. 2024-04-27. PMID:38674708. |
postprandial bile-acid levels, insulin, glucose, glp-1, c4, fgf19 and lipids were measured. |
2024-04-27 |
2024-04-29 |
Not clear |
| Maria-Christina Kanata, Amalia E Yanni, Chrysi Koliaki, Irene Pateras, Ioanna A Anastasiou, Alexander Kokkinos, Vaios T Karathano. Effects of Wheat Biscuits Enriched with Plant Proteins Incorporated into an Energy-Restricted Dietary Plan on Postprandial Metabolic Responses of Women with Overweight/Obesity. Nutrients. vol 16. issue 8. 2024-04-27. PMID:38674919. |
the responses of glucose, insulin, ghrelin, glp-1, and glicentin were evaluated over 180 min. |
2024-04-27 |
2024-04-29 |
human |
| Jenpei Lee, Yingxiao Li, Juei-Tang Cheng, I-Min Liu, Kai-Chun Chen. Development of Syringaldehyde as an Agonist of the GLP-1 Receptor to Alleviate Diabetic Disorders in Animal Models. Pharmaceuticals (Basel, Switzerland). vol 17. issue 4. 2024-04-27. PMID:38675498. |
in addition, sa stimulated insulin production in min-6 cells by activating glp-1 receptors. |
2024-04-27 |
2024-04-29 |
rat |
| Rayaz A Malik, Chii-Min Hwu, Anwar A Jammah, Juan M Arteaga-Díaz, Khier Djaballah, Valerie Pilorget, Agustina Alvarez, Carine Vera, Olga Vikulov. Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study. Diabetes, obesity & metabolism. 2024-04-19. PMID:38637981. |
to assess the impact of insulin glargine (100 u/ml) and lixisenatide (iglarlixi) fixed-ratio combination therapy on the overall management of glycaemia in patients with type 2 diabetes (t2d), previously inadequately controlled with oral antidiabetic drugs ± basal insulin or glucagon-like peptide-1 receptor agonists (glp-1 ras). |
2024-04-19 |
2024-04-21 |
Not clear |
| Giulia Angelini, Sara Russo, Geltrude Mingron. Incretin hormones, obesity and gut microbiota. Peptides. 2024-04-18. PMID:38636809. |
gip (glucose-dependent insulinotropic polypeptide) and glp-1 (glucagon-like peptide-1), which are secreted from the intestine after nutrient intake and stimulate insulin secretion from pancreatic β cells, influence lipid metabolism, gastric empting, appetite and body weight. |
2024-04-18 |
2024-04-21 |
Not clear |
| Ghinwa Barakat, Ghaith Assi, Hussein Khalil, Sami El Khati. A Comprehensive Review on GLP-1 Signaling Pathways in the Management of Diabetes Mellitus - Focus on the Potential Role of GLP-1 Receptors Agonists and Selenium Among Various Organ Systems. Current diabetes reviews. 2024-04-17. PMID:38629376. |
it has been shown that glp-1 efficiently increases insulin production, lowers blood sugar levels in patients with type 2 diabetes mellitus, and decreases appetite, craving, and hunger, therefore amplifying the sensation of fullness and satiety. |
2024-04-17 |
2024-04-19 |
Not clear |
| Anne-Sofie H Jensen, Henriette Ytting, Mikkel P Werge, Elias B Rashu, Liv E Hetland, Mira Thing, Puria Nabilou, Johan Burisch, Kirstine N Bojsen-Møller, Anders E Junker, Lise Hobolth, Christian Mortensen, Flemming Tofteng, Flemming Bendtsen, Søren Møller, Mogens Vyberg, Reza R Serizawa, Lise L Gluud, Nicolai J Wewer Albrechtse. Patients with autoimmune liver disease have glucose disturbances that mechanistically differ from steatotic liver disease. American journal of physiology. Gastrointestinal and liver physiology. 2024-04-16. PMID:38625142. |
we measured the concentrations of glucose, c-peptide, insulin, glucagon, the two incretin hormones glucose insulinotropic peptide (gip) and glucagon-like peptide-1 (glp-1). |
2024-04-16 |
2024-04-18 |
Not clear |
| Lampros G Chrysavgis, Spyridon Kazanas, Konstantina Bafa, Sophia Rozani, Maria-Evangelia Koloutsou, Evangelos Cholongita. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. International journal of molecular sciences. vol 25. issue 7. 2024-04-13. PMID:38612640. |
glucagon-like peptide 1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are incretins that regulate postprandial glucose regulation, stimulating insulin secretion from pancreatic β-cells in response to food ingestion. |
2024-04-13 |
2024-04-15 |
human |
| Junping Guo, Xinghua Chen, Cole Wang, Feng Ruan, Yunhe Xiong, Lijun Wang, Osama Abdel-Razek, Qinghe Meng, Rauf Shahbazov, Robert N Cooney, Guirong Wan. LIRAGLUTIDE ALLEVIATES ACUTE LUNG INJURY AND MORTALITY IN PNEUMONIA-INDUCED SEPSIS THROUGH REGULATING SURFACTANT PROTEIN EXPRESSION AND SECRETION. Shock (Augusta, Ga.). vol 61. issue 4. 2024-04-12. PMID:38150354. |
glucagon-like peptide 1 (glp-1) analogs are used to treat type 2 diabetes, and they can regulate insulin secretion, energy homeostasis, inflammation, and immune cell function. |
2024-04-12 |
2024-04-14 |
mouse |
| H B Carslake, G L Pinchbeck, C M Argo, A H A Dugdale, C M McGowa. Investigation of glucagon-like peptide-1 response to six oral carbohydrates in ponies. Veterinary journal (London, England : 1997). 2024-04-11. PMID:38604332. |
glucagon-like peptide-1 (glp-1), the principal incretin in horses, may play a role in the pathophysiology of insulin dysregulation (id). |
2024-04-11 |
2024-04-14 |
Not clear |
| H B Carslake, G L Pinchbeck, C M Argo, A H A Dugdale, C M McGowa. Investigation of glucagon-like peptide-1 response to six oral carbohydrates in ponies. Veterinary journal (London, England : 1997). 2024-04-11. PMID:38604332. |
glucose, insulin and glp-1 concentrations were measured before and following each intervention. |
2024-04-11 |
2024-04-14 |
Not clear |
| Zhenyu Liu, Huixi Kong, Baoyu Zhan. Narrative literature review of antidiabetic drugs' effect on hyperuricemia: elaborate on actual data and mechanisms. Endocrine connections. 2024-04-05. PMID:38579756. |
we find that insulin and dipeptidyl peptidase 4 inhibitor (dpp-4i) except linagliptin could increase the sua, and other drugs including metformin, thiazolidinediones (tzds), glucagon-like peptide-1 receptor agonists (glp-1 ras), linagliptin, sodium-glucose cotransporter 2 inhibitors (sglt2i) and α-glucosidase inhibitors have a reduction effect on sua. |
2024-04-05 |
2024-04-10 |
Not clear |
| Svjatoslavs Kistkins, Othmar Moser, Vitālijs Ankudovičs, Dmitrijs Bliznuks, Timurs Mihailovs, Sergejs Lobanovs, Harald Sourij, Andreas F H Pfeiffer, Valdis Pirag. From classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and GLP-1 for the treatment of diabesity. Endocrine connections. 2024-04-05. PMID:38579770. |
from classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and glp-1 for the treatment of diabesity. |
2024-04-05 |
2024-04-10 |
Not clear |
| Svjatoslavs Kistkins, Othmar Moser, Vitālijs Ankudovičs, Dmitrijs Bliznuks, Timurs Mihailovs, Sergejs Lobanovs, Harald Sourij, Andreas F H Pfeiffer, Valdis Pirag. From classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and GLP-1 for the treatment of diabesity. Endocrine connections. 2024-04-05. PMID:38579770. |
this review aims to provide insights into the cross-interactions of insulin, glucagon, and glp-1, revealing the complex hormonal dynamics during fasting and postprandial states, impacting glucose homeostasis, energy expenditure, and other metabolic functions. |
2024-04-05 |
2024-04-10 |
Not clear |
| Samrin Kagdi, Sulayman Lyons, Jacqueline L Beaudr. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. The Journal of endocrinology. 2024-04-05. PMID:38579777. |
glucose-dependent insulinotropic polypeptide (gip) is an incretin hormone secreted from the small intestinal k-cells, responsible for augmenting insulin release, and has gained attention for its independent and amicable effects with glucagon-like peptide-1 (glp-1), another incretin hormone secreted from the small intestinal l-cells. |
2024-04-05 |
2024-04-10 |
human |
| Samrin Kagdi, Sulayman Lyons, Jacqueline L Beaudr. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. The Journal of endocrinology. 2024-04-05. PMID:38579777. |
the gip receptor (gipr) is found in whole adipose tissue, whereas the glp-1 receptor (glp-1r) is not, and some studies suggest that gipr action lowers body weight and plays a role in lipolysis, glucose/lipid uptake/disposal, adipose tissue blood flow, lipid oxidation, and free-fatty acid (ffa) re-esterification that may or may not be influenced by other hormones such as insulin. |
2024-04-05 |
2024-04-10 |
human |
| Janet B McGill, Irl B Hirsch, Christopher G Parkin, Grazia Aleppo, Carol J Levy, James R Gavi. The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2024-04-04. PMID:38573469. |
in this narrative review, we discuss current evidence that supports glp-1 ra use in combination with insulin therapy and the potential pitfalls of reliance on glp-1 ras as a substitute for insulin therapy. |
2024-04-04 |
2024-04-06 |
Not clear |
| Elizabeth Van Dril, Margaret Allison, Christie Schumache. Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy. American heart journal plus : cardiology research and practice. vol 17. 2024-04-01. PMID:38559880. |
while the etiology of their underuse is multifactorial, lack of comfortability in adding a glp-1 receptor agonist to established insulin regimens is a common barrier. |
2024-04-01 |
2024-04-04 |
Not clear |
| Elizabeth Van Dril, Margaret Allison, Christie Schumache. Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy. American heart journal plus : cardiology research and practice. vol 17. 2024-04-01. PMID:38559880. |
adjustments to basal and bolus insulin doses upon initiation of glp-1 receptor agonists in trials have varied. |
2024-04-01 |
2024-04-04 |
Not clear |
| Elizabeth Van Dril, Margaret Allison, Christie Schumache. Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy. American heart journal plus : cardiology research and practice. vol 17. 2024-04-01. PMID:38559880. |
overall, initiation of glp-1 receptor agonists can decrease insulin requirements and may permit deintensification of antihyperglycemic therapy through the reduction or discontinuation of bolus insulin therapy. |
2024-04-01 |
2024-04-04 |
Not clear |